1 / 26

laboratoriumdiagnostiek bij heparine geinduceerde trombopenie

laboratoriumdiagnostiek bij heparine geinduceerde trombopenie. Nascholingsbijeenkomst NVKC Regio-Oost De Lutte 12 januari 2007 Henk Adriaansen KCHL, Gelre Ziekenhuizen Apeldoorn -Zutphen. Etiology of Thrombocytopenia. Decreased production

quinto
Download Presentation

laboratoriumdiagnostiek bij heparine geinduceerde trombopenie

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. laboratoriumdiagnostiek bij heparine geinduceerde trombopenie Nascholingsbijeenkomst NVKC Regio-Oost De Lutte 12 januari 2007 Henk Adriaansen KCHL, Gelre Ziekenhuizen Apeldoorn-Zutphen

  2. Etiology of Thrombocytopenia • Decreased production • Infection, chemo, alcohol, B12/folate, MDS, leukemia • Increased destruction • DIC, TTP, PTP, drugs, infection, HELLP, cardiopulmonary bypass • Dilutional or distributional • Excessive pRBC transfused, splenomegaly, pseudothrombocytopenia

  3. Pseudothrombocytopenia • About 0.3% of population • Caused by EDTA • Benign, lab only phenomena, may be intermittant • Platelet clumps on smear • Re-run CBC in citrate or heparin

  4. Drugs • List grows longer every day • Most common: • Heparin • Antibiotics • Zantac • Quinine • Antiplatelet drugs • Antiepileptics • Antiarrythmics

  5. Thrombocytopenia due to drugs • Heparin is a whole separate issue • Stop the drug & wait for recovery • Improvement usually in few days-week • No effective growth factors to date • IL-11 (Neumega) approved for chemotherapy related thrombocytopenia • Doesn’t work

  6. Heparin Induced Thrombocytopenia (HIT) • Seen in up to 10% of patients on heparin • Most are non-immune • More common with UFH than LMWH • Up to 5% with UFH • 1% with LMWH • Can be seen with heparin flushes, heparin coated catheters, heparin during dialysis

  7. HIT Type 1 • Non-immune response to heparin • Usually mild drop in platelets (>100,000) • 1-2 days after start of heparin • Often returns to normal on heparin • Usually no clinical consequence • Usually responds to simple cessation of heparin

  8. HIT Type 2 • Immune mediated • Antibody against heparin-platelet factor 4 complex • Antibody binds to Fc receptor & activates platelet • Potentially life/limb threatening condition • Leads to thrombocytopenia, arterial and venous thromboses

  9. Tests for HIT • Diagnosis is clinical • Do not wait for tests to start therapy- both are send outs and take days • Serotonin release assay – • Functional assay that looks for platelet activation • ELISA for PF 4 • Antigen assay for heparin/PF4 complex • Platelet aggregation • Geltest Diamed

  10. Functionele testen voor HIT • bloedplaatjesaggregatie test (PAT) • 14C-serotonine release test (14C-SRA) • ATP release test (lumi-aggregometry) • heparine geinduceerde bloedplaatjesactivatie test (HIPA) • flow cytometrische bepaling van bloedplaatjes micropartikels • flowcytometrische bepaling van annexine-V binding

  11. 14C-serotonine release test (14C-SRA) = gouden standaard • PRP+14C-serotonine: 15’ op 37°C • + test serum + heparine(1): 60’ op 22°C • +0.5% EDTA • centrifugatie • scintillatieteller

  12. Serotonin Release Assay • Measures the release of serotonin from aggregated platelets in serum of patient with HIT; relies on platelet aggregation in the presence of heparin • Advantages • High specificity and sensitivity • Validated in blinded assessment of a clinical trial • Disadvantages • Technically demanding and time-consuming • Requires the use of radioactive materials • Not widely available

  13. ELISA • Immunologische bepaling van HIT antilichamen • ELISA test voor heparine-PF4 antistoffen • microtiterplaat gecoat met hep-PF4 +patientenserum of positieve controle of negatieve controle, 60’ op KT • 5x wassen + antihumaan IgG,A,Mperoxidase conjugaat, 60’ op KT+ 5x wassen • ortho-phenyleen diameer/ureumperoxidase substraat,5’ op KT

  14. Tests for HIT

  15. Platelet Aggregation Assay • Measures platelet aggregation of IgG in serum or plasma of a HIT patient treated with heparin • Donor platelets can be washed or suspended in citrated plasma • Advantages • Easily performed in most laboratories • Specificity greater than 90% • Disadvantages • Low sensitivity: 35%–81%; sensitivity higher using washed platelets • Reactivity varies among donor platelets

  16. Ter discussie het Diamed Gelsysteem voor het aantonen van HIT

  17. HIT Type 2 • Thrombotic Sequelae of HIT: • Venous: arterial thrombosis = 4:1 • DVT (50%) • PE (25%) • Acute limb ischemia (10-20%) • Warfarin-associated venous limb gangrene (5-10%) • Acute thrombotic stroke or MI (3-5%)

  18. HIT Type 2 • 50% risk of thrombosis over 30 days with cessation of heparin alone • Thrombotic tendency exists for at least 40 days after stopping heparin • Overall risk of thrombotic complication: 38-76%

  19. HIT Type 2 Time course • Typically occurs 4-14 days after starting heparin • Has occurred as soon as 10 hours after re-exposure to heparin • Has occurred 3-4 days after cessation of heparin

  20. HIT Diagnosis • Consider in anyone with unexplained drop in platelets to < 150,000 or 50% decrease while on heparin • Diagnosis is clinical • Do not wait for lab test results to start treatment

  21. Pathofysiologie HIT • Verschillende componenten betrokken bij het ontstaansmechanisme van HIT: • Trombocyten • HIT-antistoffen • FcγRIIalfa isovormen • Endotheliale cellen • Leukocyten • Inflammatoire toestand J. Walenga et al., Sem. Throm. Hem., 2004 T. Warkentin, Hematology, 2003 Newman and Chong, Blood, 2000

  22. Pathofysiologie • HIT-antistoffen en bloedplaatjes • Binding van heparine aan PF4 tetrameer  neoepitope (IL8, NAP2 = CXC chemokines) • Vorming van AL tegen heparine-PF4 complex (IgG1 > IgG3 > IgG2 > IgG4 >> IgA en IgM) • Fab-regio van het AL bindt heparine-PF4 complex, terwijl het Fc-gedeelte FcγRII op de Blp-membraan bindt • Activatie van de trombocyten met • secretie van meer PF4, stollingsfactoren,... uit de alfa-granules • secretie van serotonine, ADP, Ca2+ uit de densebodies => Amplificatie • Vorming van trombocytenaggregaten

  23. Pathofysiologie • Receptor isovormen • 2 isovormen op aminozuurplaats 131: een arginine (R) of een histidine (H) • FcγRII-H bindt IgG2 met hogere affiniteit dan de FcγRII-R  hogere frekwentie HIT bij patienten met H/H genotype (Brandt et al., Denomme et al.)

More Related